Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer

摘要

AIM To assess the impact of hepatitis B surface(HBsAg)seroclearance on survival outcomes in hepatitis B-related primary liver cancer.METHODS Information from patients with hepatitis B-related liver cancer admitted in our hospital from 2008-2017 was retrieved.Cases diagnosed with HBsAg(-)and HBcAb(+)liver cancer were included in the HBsAg seroclearance(SC)group.HBsAg(+)liver cancer patients strictly matched for liver cancer stage(AJCC staging system,8th edition),Child-Pugh score,and first diagnosis/treatment method(surgery,ablation and TACE)were assigned to the HBsAg non-seroclearance(NSC)group.Then,clinical,pathological and survival data in both groups were assessed.RESULTS The SC and NSC groups comprised of 72 and 216 patients,respectively.Patient age(P0.05).Overall survival was lower in the SC group than the NSC group(P=0.019),with 1-,3-,and 5-year survival rates of 82.1%vs 85.1%,43.2%vs 56.8%,and 27.0%vs 45.2%,respectively.Survival of patients with AJCC stageⅠdisease in the SC group was lower than that of the NSC group(P=0.029).CONCLUSION Seroclearance in patients with hepatitis B-related primary liver cancer has protective effects with respect to tumorigenesis,cirrhosis,and portal hypertension but confers worse prognosis,which may be due to the frequent occurrence of highly malignant ICC and CHC.